• Expel Restenosis Rate
• Cobalt Chromium Everolimus
• Eluting Coronary Stent

The EvroSure contains Everolimus at a dose of 1.1 µg/mm² provides optimum anti-proliferation and endothelial regeneration, which in-turn assist to reduce Restenosiss.

For Unbeatable deliverbility which achieves:

Finely engineered elements of an expansive Cobalt Chromium L605 platform, enhances stent flexibility.

The blend of biodegradable PLLA and PLGA polymers with an Integrated Everolimus drug which release in approx 4 – weeks !! Ideal frame work for strength and compatibility.